CANCER IN IDAHO 2016 Preliminary

CANCER IN IDAHO 2016 Preliminary November 2017 A Publication of the Cancer Data Registry of Idaho Editors: Christopher J. Johnson, MPH, Epidemiologist Stacey L. Carson, RHIT, Vice President Operations and Registry Services Contributors: Denise Jozwik, RHIT, CTR, Director of Data Quality Patti Rose, RHIT, CTR, Data Quality & Collection Coordinator Shannon Makinen, RHIT, CTR, Data Quality & Collection Coordinator Regina Eck, Database Administrator CANCER DATA REGISTRY OF IDAHO P.O. Box 1278 Boise, Idaho 83701-1278 208-489-1380 (phone) 208-344-0180 (FAX) http://www.idcancer.org

PREFACE Cancer in Idaho - 2016," the fortieth annual report of the Cancer Data Registry of Idaho (CDRI), contains information on the cancer burden among Idaho residents, with a focus on cancer cases diagnosed during 2016. The data can be used by public health officials, hospital administrators, physicians, the Comprehensive Cancer Alliance for Idaho, and others to effectively plan services, prioritize health resource allocations, develop and measure prevention and intervention strategies, and identify high risk populations within the state of Idaho. ACKNOWLEDGMENTS The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare, Division of Public Health, to provide a statewide cancer surveillance system. The statewide cancer registry database is a product of collaboration among many report sources, including hospitals, physicians, surgery centers, pathology laboratories, and other states in which Idaho residents are diagnosed or treated for cancer. Their cooperation in reporting timely, accurate, and complete cancer data is acknowledged and sincerely appreciated. CDRI would also like to thank the Division of Public Health, Idaho Department of Health and Welfare, and the Comprehensive Cancer Alliance for Idaho for their continued partnership and for using CDRI data as a tool in cancer control and prevention. We acknowledge the Centers for Disease Control and Prevention for its support of CDRI and the distribution of this annual report under cooperative agreement 1NU58DP006270-01 awarded to the Idaho Hospital Association. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. SUGGESTED CITATION: Johnson CJ, Carson SL. Cancer in Idaho, 2016, Preliminary Data. Boise, ID: Cancer Data Registry of Idaho; November 2017. COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated. 2

Introduction to the Cancer Data Registry of Idaho (CDRI) Purpose of the Registry Population-based cancer registries are essential for assessing the extent of cancer burden in a specified geographic area. The Cancer Data Registry of Idaho (CDRI) is a population-based cancer registry that collects incidence and survival data on all cancer patients who reside in the state of Idaho or who are diagnosed or treated for cancer in the state of Idaho. The goals of CDRI are to: determine the incidence of cancer in the state of Idaho with respect to geographic, demographic, and social characteristics; monitor trends and patterns of cancer incidence over time; identify high-risk populations; provide a database and serve as a resource for conducting epidemiologic studies; and provide data to assist public health officials, hospital administrators, and physicians to effectively plan services, prioritize health resource allocations and develop and measure prevention and intervention strategies. CDRI works closely with the Comprehensive Cancer Alliance for Idaho (CCAI), the Idaho Comprehensive Cancer Control Program, and other organizations to lessen the burden of cancer in Idaho. History and Funding of the Registry CDRI was established in 1969 and became population-based in 1971. The Idaho State Legislature has provided guidelines for the establishment, requirements, and funding of the statewide cancer registry. The operations of the registry are mandated by Idaho Code 57-1703 through 57-1707. Funding is appropriated in Idaho Code 57-1701 and 63-2520, which delineates a portion (less than one percent) of the cigarette tax to be dedicated to fund the statewide cancer registry. Through the National Program of Cancer Registries (NPCR), additional funding has been awarded to CDRI from the Centers for Disease Control and Prevention (CDC) to enhance timely, complete, and accurate data collection, computerization, and reporting of reliable data. Collection of Data Each Idaho hospital, outpatient surgery center, and pathology laboratory is responsible for the complete ascertainment of all data on cancer diagnoses and treatments provided in its facility within six months of diagnosis. Sources for identifying eligible cases include: hospitals, outpatient surgery centers, private pathology laboratories, free-standing radiation centers, physicians (for patients not receiving cancer diagnoses or treatment in the above sources), death certificates, and other state cancer registries reporting an Idaho resident with cancer (as negotiated). When a cancer case is reported from more than one source, the information is consolidated into one record. Reported cases contain the following data: patient demographics (including geographic place of residence at time of cancer diagnosis); description of cancer (including date of diagnosis, primary site, metastatic sites, histology, extent of disease, etc.); first course of treatment; and follow-up data for purpose of calculating survival rates. 3

Primary site, behavior, grade, and histology were coded according to the International Classification of Diseases for Oncology, 3rd edition. 1 Stage of disease variables were coded using SEER s Summary Staging Manual 2000 and the AJCC Manual for Staging of Cancer, 7th edition, which were used to calculate NPCR-derived clinical and pathologic stage group. 2,3,4 All other variables were coded following the rules of the North American Association of Central Cancer Registries (NAACCR), the National Cancer Institute s SEER program, and the American College of Surgeons Commission on Cancer. 5-8 Beginning with cases diagnosed in 2010, new rules for coding hematopoietic and lymphoid neoplasms were applied. 9 Reportable Cases All in situ and malignant neoplasms are reportable to CDRI. The database includes all cases of carcinoma, sarcoma, melanoma, lymphoma, and leukemia, diagnosed by histology/cytology, radiology, laboratory testing, clinical observation, and autopsy. Also reportable are benign tumors of the brain, meninges, spinal cord, any other part of the central nervous system, pineal gland, and pituitary gland. Basal and squamous cell carcinomas of the skin are excluded except when occurring on a mucous membrane or if the AJCC stage group is II, III, or IV. Under Idaho Code and as recommended by NAACCR, cervix in situ cases are not currently reportable. Confidentiality of Data Idaho state law ensures the protection of confidential data and restricts the release of identifying data. Only aggregate data are published. The same law protects report sources from any liability for reporting confidential data to CDRI. Persons with access to confidential data are required to sign a pledge of confidentiality and are subject to penalty if they, through negligence or willful misconduct, disclose confidential data. Quality Assurance To assure validity and reliability of data presented, CDRI has many mechanisms in place to check data for quality and completeness. CDRI uses GenEDITS Plus software which has standard edits using algorithms that check the content of data fields against an encoded set of acceptable possible contents and flags the acceptability of coded data. Edits include field edits, interfield edits, and inter-record edits. Edits check for unlikely sex/site, site/histology, and site/age combinations. Records are also routinely checked for duplicate entries. Duplicate case checking is performed both manually and electronically using several methodologies. CDRI has met NPCR program standards and is recognized as a gold standard registry for quality, completeness, and timeliness as designated by NAACCR. These designations enable Idaho data to be included in United States Cancer Statistics and all NAACCR volumes of Cancer Incidence in North America. 4

2016 Idaho Cancer Incidence Rates by Sex (Preliminary) Total Male Female Primary Site Rate Cases Pop Rate Cases Pop Rate Cases Pop All Sites 430.5 8,250 1,683,140 459.6 4,241 843,532 409.1 4,009 839,608 Bladder 20.2 397 1,683,140 34.3 311 843,532 8.2 86 839,608 Brain - malignant 5.7 109 1,683,140 7.4 70 843,532 4.1 39 839,608 Brain and other CNS - non-malignant 10.6 194 1,683,140 7.4 65 843,532 13.6 129 839,608 Breast 62.7 1,200 1,683,140 1.0 9 843,532 121.0 1,191 839,608 Breast - in situ 9.7 178 1,683,140 0.1 1 843,532 19.0 177 839,608 Cervix 3.9 62 1,683,140 0.0 0 843,532 7.8 62 839,608 Colorectal 33.9 644 1,683,140 39.4 356 843,532 29.2 288 839,608 Corpus Uteri 13.7 274 1,683,140 0.0 0 843,532 26.6 274 839,608 Esophagus 5.0 101 1,683,140 9.0 84 843,532 1.5 17 839,608 Hodgkin Lymphoma 2.0 32 1,683,140 1.8 14 843,532 2.2 18 839,608 Kidney and Renal Pelvis 15.1 289 1,683,140 19.0 177 843,532 11.5 112 839,608 Larynx 2.3 47 1,683,140 3.0 30 843,532 1.7 17 839,608 Leukemia 14.3 265 1,683,140 18.7 167 843,532 10.3 98 839,608 Liver and Bile Duct 7.3 147 1,683,140 11.7 114 843,532 3.3 33 839,608 Lung and Bronchus 47.4 920 1,683,140 51.4 464 843,532 44.4 456 839,608 Melanoma of the Skin 28.8 530 1,683,140 33.6 299 843,532 25.1 231 839,608 Myeloma 6.5 127 1,683,140 8.3 76 843,532 4.8 51 839,608 Non-Hodgkin Lymphoma 19.9 378 1,683,140 22.7 204 843,532 17.3 174 839,608 Oral Cavity and Pharynx 12.9 253 1,683,140 19.6 187 843,532 6.8 66 839,608 Ovary 5.7 110 1,683,140 0.0 0 843,532 10.8 110 839,608 Pancreas 12.6 245 1,683,140 13.1 124 843,532 12.0 121 839,608 Prostate 49.2 1,012 1,683,140 102.8 1,012 843,532 0.0 0 839,608 Stomach 5.1 94 1,683,140 6.3 58 843,532 3.8 36 839,608 Testis 3.8 61 1,683,140 7.6 61 843,532 0.0 0 839,608 Thyroid 15.7 264 1,683,140 8.1 69 843,532 23.4 195 839,608 Pediatric Age 0 to 19 16.5 79 481,885 17.2 42 246,402 15.8 37 235,483 Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard. 5

2016 Idaho Cancer Incidence Counts by Behavior (Preliminary) Primary Site In situ Malignant All Sites 861 8,047 Bladder 203 194 Brain 0 109 Breast 178 1,200 Cervix 0 62 Colorectal 15 644 Corpus Uteri 4 274 Esophagus 0 101 Hodgkin Lymphoma 0 32 Kidney and Renal Pelvis 5 289 Larynx 1 47 Leukemia 0 265 Liver and Bile Duct 0 147 Lung and Bronchus 2 920 Melanoma of the Skin 421 530 Myeloma 0 127 Non-Hodgkin Lymphoma 0 378 Oral Cavity and Pharynx 8 253 Ovary 0 110 Pancreas 1 245 Prostate 1 1,012 Stomach 1 94 Testis 0 61 Thyroid 0 264 Pediatric Age 0 to 19 1 79 6

2016 Idaho Cancer Incidence Counts by SEER Summary Stage (Preliminary) Primary Site In situ Localized Regional Distant Unstaged All Sites 861 3,597 1,622 1,871 957 Bladder 203 108 43 13 30 Brain 0 76 15 1 17 Breast 178 766 337 62 35 Cervix 0 31 19 8 4 Colorectal 15 201 264 126 53 Corpus Uteri 4 182 38 24 30 Esophagus 0 11 36 31 23 Hodgkin Lymphoma 0 1 15 15 1 Kidney and Renal Pelvis 5 194 40 40 15 Larynx 1 24 12 6 5 Leukemia 0 0 0 232 33 Liver and Bile Duct 0 50 24 32 41 Lung and Bronchus 2 242 159 414 105 Melanoma of the Skin 421 464 34 20 12 Myeloma 0 9 0 108 10 Non-Hodgkin Lymphoma 0 84 55 193 46 Oral Cavity and Pharynx 8 111 104 23 15 Ovary 0 19 17 54 20 Pancreas 1 31 62 113 39 Prostate 1 609 130 82 191 Stomach 1 22 25 32 15 Testis 0 44 10 5 2 Thyroid 0 165 83 8 8 Pediatric Age 0 to 19 1 28 15 32 4 2016 Idaho Cancer Incidence Rates by Age (Preliminary) Age at Diagnosis Rate Cases Pop 00-04 21.7 25 115,289 05-09 9.0 11 122,679 10-14 12.0 15 125,126 15-19 23.6 28 118,791 20-24 45.6 51 111,851 25-29 43.8 49 111,817 30-34 88.4 97 109,744 35-39 153.4 166 108,209 40-44 205.6 201 97,786 45-49 329.0 323 98,182 50-54 478.0 480 100,427 55-59 757.5 813 107,320 60-64 1,057.2 1,067 100,930 65-69 1,496.8 1,347 89,990 70-74 1,822.7 1,162 63,750 75-79 2,240.8 984 43,912 80-84 2,505.0 724 28,902 85+ 2,486.4 707 28,435 Rates are per 100,000. 7

2016 Idaho Cancer Mortality Rates by Sex (Final) Total Male Female Cause of Death Rate Deaths Pop Rate Deaths Pop Rate Deaths Pop All Causes of Death 726.6 13,370 1,683,140 829.2 6,937 843,532 633.5 6,433 839,608 All Malignant Cancers 151.5 2,888 1,683,140 173.6 1,531 843,532 133.5 1,357 839,608 Bladder 4.7 90 1,683,140 7.5 64 843,532 2.4 26 839,608 Brain and Other Nervous System 5.2 99 1,683,140 6.7 61 843,532 3.8 38 839,608 Breast 11.3 217 1,683,140 0.2 2 843,532 21.2 215 839,608 Cervix 1.1 18 1,683,140 0.0 0 843,532 2.1 18 839,608 Colorectal 13.1 244 1,683,140 14.6 129 843,532 11.5 115 839,608 Corpus Uteri 1.9 37 1,683,140 0.0 0 843,532 3.5 37 839,608 Esophagus 4.3 87 1,683,140 7.6 71 843,532 1.5 16 839,608 Hodgkin Lymphoma 0.2 3 1,683,140 0.2 2 843,532 0.1 1 839,608 Kidney 3.1 60 1,683,140 3.9 34 843,532 2.5 26 839,608 Larynx 0.5 11 1,683,140 0.9 8 843,532 0.3 3 839,608 Leukemia 7.1 129 1,683,140 9.2 79 843,532 5.2 50 839,608 Liver and Bile Duct 6.6 135 1,683,140 9.7 96 843,532 3.7 39 839,608 Lung and Bronchus 30.7 582 1,683,140 36.0 314 843,532 26.5 268 839,608 Melanoma of the Skin 2.9 54 1,683,140 4.1 36 843,532 1.9 18 839,608 Myeloma 3.9 73 1,683,140 4.7 41 843,532 3.2 32 839,608 Non-Hodgkin Lymphoma 6.7 126 1,683,140 7.8 68 843,532 5.5 58 839,608 Oral Cavity and Pharynx 1.9 37 1,683,140 2.3 20 843,532 1.6 17 839,608 Ovary 4.6 92 1,683,140 0.0 0 843,532 8.7 92 839,608 Pancreas 10.4 203 1,683,140 11.8 112 843,532 8.9 91 839,608 Prostate 9.9 183 1,683,140 22.7 183 843,532 0.0 0 839,608 Stomach 2.3 43 1,683,140 2.3 21 843,532 2.3 22 839,608 Testis 0.1 2 1,683,140 0.2 2 843,532 0.0 0 839,608 Thyroid 0.7 15 1,683,140 0.9 8 843,532 0.6 7 839,608 Data source: Bureau of Vital Records and Health Statistics (BVRHS), Idaho Department of Health and Welfare, 2017. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard. Cause of death categories are based on SEER cause of death recodes (http://seer.cancer.gov/codrecode/), which differ from official BVRHS cancer mortality categories. Death counts may differ from official BVRHS statistics due to late filings. 8

REFERENCES 1. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000. 2. Young JL Jr., Roffers SD, Reis LAG, Fritz AG, Hurlbut AA (eds). SEER Summary Staging Manual 2000: Codes and Coding Instructions. National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. 3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual, 7th Edition. American Joint Committee on Cancer, Chicago IL. Springer: 2010. 4. National Program of Cancer Registries Derived Clinical and Pathologic Stage Group. Based on AJCC 7th Edition Staging. Centers for Disease Control and Prevention. Initial release: June 30, 2017. Available at: https://www.cdc.gov/cancer/npcr/tools/tnmstaging/index.htm. 5. Thornton ML, (ed). Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Record Layout Version 16, 20th ed. Springfield, Ill.: North American Association of Central Cancer Registries, September 2015, revised November 2015. Available at: https://www.naaccr.org/data-standards-data-dictionary/. 6. Adamo M, Dickie, L, Ruhl J. (January 2016). SEER Program Coding and Staging Manual 2016. National Cancer Institute, Bethesda, MD 20850-9765. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Available at: https://seer.cancer.gov/manuals/2016/spcsm_2016_maindoc.pdf. 7. Commission on Cancer. Facility Oncology Registry Data Standards (FORDS): Revised for 2016. Chicago, IL: American College of Surgeons Commission on Cancer. Available at: https://www.facs.org/qualityprograms/cancer/ncdb/registrymanuals/cocmanuals/fordsmanual. 8. Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK. The 2007 Multiple Primary and Histology Coding Rules. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD, 2007. Available at: https://seer.cancer.gov/tools/mphrules. 9. Ruhl J, Adamo M, Dickie L. (January 2015). Hematopoietic and Lymphoid Neoplasm Coding Manual. National Cancer Institute, Bethesda, MD 20850-9765. Available at: https://seer.cancer.gov/tools/heme/hematopoietic_instructions_and_rules.pdf. 10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: National Program of Cancer Registries (NPCR) and SEER Incidence Public Use Data, 2001-2014, released June 2017. These data were provided by central cancer registries participating in the NPCR and SEER Programs and submitted in November 2016. 11. Copeland G, Lake A, Firth R, Wohler B, Wu XC, Schymura M, De P, Hofferkamp J, Sherman R, Kohler B (eds). Cancer in North America: 2010-2014, Volume Two: Registry-Specific Cancer Incidence in the United States and Canada. Springfield, Ill.: North American Association of Central Cancer Registries, June 2017, pp 151-160. Available at: https://www.naaccr.org/cancer-in-north-america-cina-volumes/#vol2. 12. National Center for Health Statistics. Vintage 2016 postcensal estimates of the resident population of the United States (April 1, 2010, July 1, 2010-July 1, 2016), by year, county, single-year of age (0, 1, 2,.. 85 years and over), bridged race, Hispanic origin, and sex. Prepared under a collaborative arrangement with the U.S. Census Bureau. Available from: http://www.cdc.gov/nchs/nvss/bridged_race.htm as of June 26, 2017, following release by the U.S. Census Bureau of the unbridged Vintage 2016 postcensal estimates by 5-year age group on June 22, 2017. 13. Schottenfeld D, Fraumeni JF Jr. (Eds). Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996. 14. Lenhard RE, Osteen RT, Gansler T (Eds). Clinical Oncology. The American Cancer Society, Inc.: Atlanta; 2001. 15. Report on Carcinogens, Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program; 2005. 16. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2016 Sub (2000-2014) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2015 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2017, based on the November 2016 submission. 17. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.3; Statistical Research and Applications Branch, National Cancer Institute, 2005. Available at: https://surveillance.cancer.gov/devcan. 18. Joinpoint Regression Program, Version 4.2.0.2. June 2015; Statistical Research and Applications Branch, National Cancer Institute. Available at: https://surveillance.cancer.gov/joinpoint. 19. Final 2016 mortality data, Bureau of Vital Records and Health Statistics, Idaho Department of Health and Welfare; October 2017. 9

20. Cronin KA, Feuer EJ. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med 2000 Jul 15;19(13):1729-40. 21. Ellison LF. Adjusting relative survival estimates for cancer mortality in the general population. Statistics Canada, Catalogue no. 82-003-X, Health Reports, Vol. 25, no. 11, pp. 3-9, November 2014. 22. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data. J Natl Cancer Inst 2010 Oct 20;102(20):1584-98. Epub 2010 Oct 11. 23. Ederer F, Heise H (1959). Instructions to IBM 650 programmers in processing survival computations, methodological note 10. End Results Evaluation Section, National Cancer Institute. 24. Mariotto AB, Zou J, Johnson CJ, Weir HK, Scoppa S, Huang B. Geographical, racial and socio-economic variation in life expectancy in the US and their impact on cancer relative survival. Submitted 2017. 25. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004 Oct;40(15):2307-16. 10

APPENDIX A 2000 U.S. STANDARD POPULATION Age Group 2000 US Standard Population (Census P25-1130) 0 3,794,901 1-4 15,191,619 5-9 19,919,840 10-14 20,056,779 15-19 19,819,518 20-24 18,257,225 25-29 17,722,067 30-34 19,511,370 35-39 22,179,956 40-44 22,479,229 45-49 19,805,793 50-54 17,224,359 55-59 13,307,234 60-64 10,654,272 65-69 9,409,940 70-74 8,725,574 75-79 7,414,559 80-84 4,900,234 85+ 4,259,173 Total 274,633,642 Source: SEER Program, National Cancer Institute, 2017. 16 11